Dr. Richard Gliklich, MD is the founder of OM1, Inc. Previously, he was founder and CEO of Outcome, which he led from inception through its acquisition by Quintiles.

Dr. Gliklich is well known in the areas of registries, outcomes and analytics. He is senior editor of the landmark publication by the U.S. Agency for Healthcare Research and Quality (AHRQ) handbook "Registries for Evaluating Patient Outcomes: A User's Guide” and the PI for the Outcomes Measures Framework, which focuses on standardization of outcomes measurement. He has led several key national and international efforts focused on evaluating the safety, effectiveness, value and quality of healthcare. Dr. Gliklich also holds several patents for both health outcomes systems and medical devices.

Dr. Gliklich is a graduate of Yale University and Harvard Medical School and a former Charles A. Dana Scholar at the University of Pennsylvania. He is also a surgeon and the Leffenfeld Professor at Harvard Medical School.

Catherine Richards, PhD, MPH

Catherine Richards is the President & COO at OM1, inc. In her role as president Catherine is responsible for leading OM1’s four business units: Data & Insights, ASPEN, Research Services and PhenOM, as well as leads technology and compliance, all with the goal of ensuring a thriving company culture that delivers significant value to customers.

Prior to OM1 Catherine was the Chief Data Officer & General Manager of the Real World Evidence business unit at ConcertAI, where she was responsible for a 600+ person global team that created and delivered data products, custom data solutions and outcomes science services to the pharmaceutical industry.

Before ConcertAI, she was the Senior Vice President of Analytics & Scientific Engagement at Panalgo, where she led data integration, data operations and scientific engagement, including training and supporting users of Instant Health Data (IHD).

Previous to Panalgo she was the Director of User and Scientific Engagement for Aetion, supporting the use and adoption of the Aetion Evidence Platform and working as the scientific lead for five of the top 20 pharmaceutical companies.

Proceeding Aetion she was a staff scientist at the Hutchinson Institute for Cancer Outcomes Research (HICOR) at Fred Hutch in Seattle, Washington. While there the main focus of her research and academic activities was on improving the quality of cancer care while reducing the economic burden for patients and society.

Catherine received her MPH and PhD in Cancer Epidemiology from the Mailman School of Public Health At Columbia University.

Dan Levy is the Chief Data Officer at OM1, Inc. In his role, Dan is responsible for developing and managing the partner ecosystem, with a focus on creating data solutions that generate value to both OM1 customers and partners.

For the prior 4 years, Dan was Chief Technology Officer at Amazing Charts, an ambulatory electronic medical record and health IT company. Dan led the software engineering, quality assurance, cloud operations, and data & analytics functions, and helped lead the company through an acquisition to Harris Healthcare. For the 8 years prior, Dan served as Vice President of Engineering and later as Chief Technology Officer at Outcome Sciences, a division of Quintiles, focusing on real-world and late phase research.  Prior to that, Dan held a number of technical leadership roles in both public and private, venture backed companies.

Dan received a BA in General Science from Brandeis University and an MS in Software Engineering from Boston University.

Rich Jenkins has 25 years experience  in the life sciences technology and real-world research space. Rich spent the previous 6 years as Chief Growth Officer at Aetion, where he led their significant growth in the RWE market. Formerly the global head of Real-World and Late Phase Business Development with IQVIA, Rich was responsible for developing and leading go-to-market strategy for IQVIA’s Real-World Insights business. Richard joined IQVIA (Quintiles) through the acquisition of Outcome Sciences. From 2006-2008, Rich was the vice president, Global Business Development of ArisGlobal, a SaaS business selling solutions into the life sciences industry. Prior to joining ArisGlobal, Rich spent seven years with IntraLinks, an online secure platform supporting information for clinical trials, M&A due diligence, and syndicated financing. He played a critical role in transitioning the core customer base from financial services and legal to key stakeholders across the life sciences industry.

Jenkins holds a Bachelor's of Engineering in Electrical Engineering from Stony Brook University.

Eric Schrock is the Chief Technology Officer at OM1, Inc. In this role, he is responsible for the Product Engineering, Data Engineering, IT, and Security teams that develop and operate OM1's technology platform and products.

Prior to OM1, Eric was the Chief Technology Officer and Co-CEO at Jvion, a clinical AI company that uses prescriptive intelligence to improve patient outcomes. There, he ran the engineering, data science, professional services, and customer success teams responsible for product development and delivery. Prior to Jvion, Eric was VP of Engineering and CTO at Delphix, a data virtualization company that simplifies the delivery of secure production data to enterprise teams. Early in his career, Eric developed complex enterprise software systems including operating systems, filesystems, and hardware storage appliances.

Costas Boussios, PhD is the Chief Data Scientist at OM1, where he leads research and development of OM1's AI solutions. Prior to OM1, Dr. Boussios was the Chief Data Scientist at Mitra Capital LLC, the top performing equity market neutral fund of 2015. He has also led Data Science at Cignifi Inc, where he developed credit scoring solutions using mobile telephony data for millions of unbanked consumers in developing countries, and at Zakipoint Health LLC, where he developed patent-pending technology in optimization of health goal program engagement and adherence. He has also held the position of Director of Analytics at D&B working on commercial credit and insolvency risk scoring. Dr. Boussios holds a PhD from Mechanical Engineering at MIT with specialization in Machine Learning and Feedback Control Systems.

Kathryn is the Vice President of Real World Evidence at OM1. Previously, she was the Senior Director of Epidemiology and Outcomes Research at Outcome (now part of the late phase division of IQVIA).

Prior to Outcome, she served as lead for safety and risk management for products from clinical development through to post-marketing, with particular expertise in rare diseases, biologics and gene therapy applications at Genzyme. She has also held research positions at the NIH, Columbia and Harvard.

Kathryn is a graduate of Dartmouth College and the Harvard T.H. Chan School of Public Health.

Dr. Carl Marci is the Chief Clinical Officer and Chief Psychiatrist and Managing Director of Mental Health and Neuroscience at OM1. Previously, he was Chief Psychiatrist and Chief Medical Officer at several venture backed health and technology companies, and is a 2023 PharmaVoice 100 Honoree.

Dr. Marci is board certified and is part-time staff at Massachusetts General Hospital and Assistant Professor of Psychiatry at Harvard Medical School, he completed two NIH Fellowships in neuroscience and has published numerous articles in peer-review science journals. He holds seven patents and is the author of a book on the impact of technology on the brain.

Dr. Marci is a graduate of Columbia University and Oxford University where he was a Rhodes Scholar. He then went to Harvard Medical School and graduated with honors; he is also the former Director of Social Neuroscience at Massachusetts General Hospital.

Joseph Zabinski, PhD, MEM is VP, Head of Commercial Strategy & AI at OM1. He oversees design, implementation, and evolution of OM1's commercial strategy, including prioritization, go-to-market planning, and alignment with emergent market needs. Dr. Zabinski also serves as subject matter expert and thought leader for OM1's AI work, including applications of the PhenOM digital phenotyping platform with life science and healthcare provider partners.Prior to joining OM1, Dr. Zabinski was a consultant in the Pharmaceutical and Medical Products Practice at McKinsey & Co. He specialized in advising life science and healthcare clients on using AI and advanced analytics, including identification of unmet medical needs, portfolio optimization, and AI strategy. His academic research focused on applications of Bayesian network modeling methods to predicting and stratifying environmental human health risk.Dr. Zabinski holds a master’s degree in engineering management from Dartmouth College, and a doctorate with a focus in health analytics from the School of Public Health at the University of North Carolina, Chapel Hill.

Joe is a 2023 Healthcare Innovation 40 Under 40 Winner.

Tom Engel is the Vice President of Business Development for OM1, Inc. Previously, Tom led the US Sales Team for QuintilesIMS Real World Evidence following the merger of Quintiles and IMS Health. Prior to the merger, Tom led the North America Sales Team for Real World and Late Phase Research at Quintiles (NYSE: Q), the world's largest Clinical Research Organization (CRO). In 2004, Tom joined Rich Gliklich at Outcome Sciences, Inc. (Outcome) where he focused on sales and market development through the 2011 acquisition of Outcome by Quintiles.

In 1998, Tom joined Phase Forward (later acquired by Oracle) as the first Product Manager for InForm, the market-leading electronic data capture system for clinical development. He joined IntraLinks, Inc. in 2002 as Vice President of Strategic Business Development tasked to develop new sales channels for IntraLinks’ clinical products.

Tom received his Bachelor of Arts degree from Boston College in Mathematics a very long time ago. When not at home with his family, Tom can be found walking in the woods or on the nearest mountain.

Kristine Christie has over 15 years of marketing experience with SaaS and services companies in the life sciences and healthcare industries. Her most recent role was Vice President of Marketing at ArisGlobal, where she grew and led a cross-functional team responsible for developing and executing go-to-market strategies, positioning and messaging, sales enablement, content, and bid management to drive revenue growth across four SaaS product portfolios.

Before ArisGlobal, Kristine was the Director of Marketing for Certara's Software division. She expanded the marketing function there and developed strategic marketing and product launch plans to support and drive Software growth.

Madelyn is the Chief People Officer at OM1, Inc., where she leads the organization’s people
strategy, helping OM1 continue to build a community of diverse and high-performing talent and cultivate an inclusive, empowering and connected employee experience.

Prior to OM1, Madelyn was the Vice President of People at Kyruus, Inc. where she led the
People team’s efforts across Talent Acquisition, Talent Development, Employee Relations, Total Rewards, and Diversity, Equity, Inclusion & Belonging. Prior to Kyruus, Madelyn served as Senior Director, HR Business Partner and Head of Talent Development at Ascend Learning, an education technology company supporting students and educators in areas of Healthcare, Fitness & Wellness, and Safety & Security.

Before launching her career in human resources, Madelyn spent several years as an external consultant in areas of Talent Management / Development and Organizational Change, serving both multinational corporations as well as small businesses and non-profit organizations.

Madelyn received a BA in Psychology from Connecticut College and an MA in Social and
Organizational Psychology from Columbia University.

Dennis Reilly is the Chief Financial Officer at OM1, Inc. Prior to joining OM1, he was the VP, Finance at Aptus Health, a global digital health company acquired by WebMD. Prior to Aptus, Dennis worked at several venture-backed healthcare technology companies.

Dennis began his career at Arthur Andersen as a CPA and corporate auditor. He received his BS from Merrimack College.